Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Orozco Morales, Mario ^a   Soca Chafre, Giovanny ^a   Barrios Bernal, Pedro ^a   Hernández Pedro, Norma ^a   Arrieta, Oscar ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; AUTACOID; CD47 PROTEIN, HUMAN;

HUMAN; IMMUNE EVASION; INFLAMMATION; LUNG CANCER; MACROPHAGE; MOLECULAR INTERACTION; NEUTROPHIL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED NEUTROPHIL; ANIMAL; IMMUNOLOGY; LUNG TUMOR; METABOLISM; TUMOR MICROENVIRONMENT;

ANIMALS; CD47 ANTIGEN; HUMANS; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; MACROPHAGES; NEUTROPHILS; TUMOR MICROENVIRONMENT;

EID: 84958213390     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/3494608     Document Type: Review

References (131)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
2. O. Arrieta, E. Guzmán-de Alba, L. F. Alba-López et al., "National consensus of diagnosis and treatment of non-small cell lung cancer," Revista de Investigacion Clinica, vol. 65, supplement 1, pp. S5-S84, 2013.
3. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.
4. R. S. Herbst, J. V. Heymach, and S. M. Lippman, "Lungcancer," The New England Journal of Medicine, vol. 359, no. 13, pp. 1367- 1380, 2008.
5. W. D. Travis, "Pathology of lung cancer," Clinics in Chest Medicine, vol. 32, no. 4, pp. 669-692, 2011.
6. S. S. Devesa, F. Bray, A. P. Vizcaino, and D. M. Parkin, "International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising," International Journal of Cancer, vol. 117, no. 2, pp. 294-299, 2005.
7. P. Boyle and B. Levin, World Cancer Report 2008, WorldHealth Organization, 2008.
8. S. Sun, J. H. Schiller, and A. F. Gazdar, "Lung cancer in never smokers - a different disease," Nature Reviews Cancer, vol.7, no. 10, pp. 778-790, 2007.
9. O. Arrieta, M. A. Rios Trejo, and R. M. Michel, "Wood-smoke exposure as a response and survival predictor in erlotinibtreated nonsmall cell lung cancer patients," Journal of Thoracic Oncology, vol. 4, no. 8, p. 1043, 2009.
10. O. Arrieta, L. A. Ramirez-Tirado, R. Baez-Saldana, O. Pena-Curiel, G. Soca-Chafre, and E. O. Macedo-Perez, "Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the 'Hispanic paradox'," Lung Cancer, vol. 90, no. 2, pp. 161-166, 2015.
11. O. Arrieta, A. D. Campos-Parra, C. Zuloaga et al., "Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure," Journal of Thoracic Oncology, vol. 7, no. 8, pp. 1228-1234, 2012.
12. U. Nur, M. Quaresma, B. De Stavola, M. Peake, and B. Rachet, "Inequalities in non-small cell lung cancer treatment and mortality," Journal of Epidemiology and Community Health, vol. 69, no. 10, pp. 985-992, 2015.
13. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma," The New England Journal of Medicine, vol. 361, no. 10, pp. 947-957, 2009.
14. O. Arrieta, P. Anaya, V. Morales-Oyarvide, L. A. Ramírez-Tirado,, and A. C. Polanco, "Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel," The European Journal of Health Economics, 2015.
15. R. Rosell, E. Carcereny, R. Gervais et al., "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial," The Lancet Oncology, vol. 13, no. 3, pp. 239-246, 2012.
16. O. Arrieta, L. Martinez-Barrera, S. Treviño et al., "Wood-smoke exposure as a response and survival predictor in erlotinibtreated non-small cell lung cancer patients: an open label phase II study," Journal of Thoracic Oncology, vol. 3, no. 8, pp. 887-893, 2008.
17. K. Suzawa, S. Toyooka, M. Sakaguchi et al., "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations," Cancer Science, 2015.
18. O. Arrieta, M. De la Torre-Vallejo, D. Lopez-Macias et al., "Nutritional status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer," The Oncologist, vol. 20, no. 8, pp. 967-974, 2015.
19. O. Arrieta, M. T. Vega-González, D. López-Macías et al., "Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients," Lung Cancer, vol. 88, no. 3, pp. 282- 288, 2015.
20. E. Dudnik, T. Siegal, L. Zach et al., "Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy," Journal of Clinical Neuroscience, 2015.
21. S. I. Ou, J. S. Ahn, L. De Petris et al., "Alectinib in crizotinibrefractory ALK-rearranged non-small-cell lung cancer: a phase II global study," Journal of Clinical Oncology, 2015.
22. E. G. Leprieur, V. Fallet, and M. Wislez, "Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer," Bulletin du Cancer, vol. 102, no. 12, pp. 1053-1057, 2015.
23. R. Rosell, T. Moran, C. Queralt et al., "Screening for epidermal growth factor receptor mutations in lung cancer," The New England Journal of Medicine, vol. 361, no. 10, pp. 958-967, 2009.
24. H. Shigematsu, L. Lin, T. Takahashi et al., "Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers," Journal of the National Cancer Institute, vol. 97, no. 5, pp. 339-346, 2005.
25. J. G. Paez, P. A. Jänne, J. C. Lee et al., "EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy," Science, vol. 304, no. 5676, pp. 1497-1500, 2004.
26. C. Villarreal-Garza, D. de la Mata, D. G. Zavala, E. O. MacEdo-Perez, and O. Arrieta, "Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases," Clinical Lung Cancer, vol.14, no. 1, pp. 6-13, 2013.
27. J. K. Yun, M. A. Kim, C. M. Choi et al., "Surgical outcomes after pulmonary resection for non-small cell lung cancer with localized pleural seeding first detected during surgery, " The Thoracic and Cardiovascular Surgeon, 2015.
28. W. Liu, Y. Shao, B. Guan et al., "Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection," International Journal of Clinical and Experimental Pathology, vol. 8, no. 9, pp.11268-11277, 2015.
29. N. M. La-Beck, G. W. Jean, C. Huynh, S. K. Alzghari, and D. B. Lowe, "Immune checkpoint inhibitors: new insights and current place in cancer therapy," Pharmacotherapy, vol. 35, no. 10, pp. 963-976, 2015.
30. J. C. Soria, A. Marabelle, J. R. Brahmer, and S. Gettinger, "Immune checkpoint modulation for non-small cell lung cancer," Clinical Cancer Research, vol. 21, no. 10, pp. 2256-2262, 2015.
31. S. L. Scarpace, "Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies," Drugs in Context, vol. 4, Article ID 212289, 2015.
32. T. O. Dang, A. Ogunniyi, M. S. Barbee, and A. Drilon, "Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer," Expert Review of Anticancer Therapy, vol. 16, no. 1, pp. 13-20, 2015.
33. A. Patnaik, S. P. Kang, D. Rasco et al., "Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors," Clinical Cancer Research, vol. 21, no. 19, pp. 4286-4293, 2015.
34. A. Gunturi and D. F. McDermott, "Nivolumab for the treatment of cancer," Expert Opinion on Investigational Drugs, vol. 24, no. 2, pp. 253-260, 2015.
35. H. Borghaei, L. Paz-Ares, L.Horn et al.,"Nivolumabversusdocetaxel in advanced nonsquamous non-small-cell lung cancer," The New England Journal of Medicine, vol. 373, no. 17, pp. 1627- 1639, 2015.
36. J. Villadolid and A. Amin, "Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities," Translational Lung Cancer Research, vol. 4, no. 5, pp. 560-575, 2015.
37. E. Rossi, A. Sgambato, G. Chiara et al., "Endocrinopathies induced by immune-checkpoint inhibitors in advanced nonsmall cell lung cancer," Expert Review of Clinical Pharmacology, 2015.
38. J. Lu, L. Lee-Gabel, M. C. Nadeau, T. M. Ferencz, and S. A. Soefje, "Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy," Journal of Oncology Pharmacy Practice, vol. 21, no. 6, pp. 451-467, 2015.
39. Y. Wu and B. P. Zhou, "Inflammation: a driving force speeds cancer metastasis," Cell Cycle, vol. 8, no. 20, pp. 3267-3273, 2009.
40. G. Sethi, M. K. Shanmugam, L. Ramachandran, A. P. Kumar, and V. Tergaonkar, "Multifaceted link between cancer and inflammation," Bioscience Reports, vol. 32, no. 1, pp. 1-15, 2012.
41. S. Jaillon, M. R. Galdiero, D. Del Prete, M. A. Cassatella, C. Garlanda, and A. Mantovani, "Neutrophils in innate and adaptive immunity," Seminars in Immunopathology, vol. 35, no. 4, pp. 377-394, 2013.
42. L. Barrera, E. Montes-Servín, A. Barrera et al., "Cytokine profile determined by data-mining analysis set into clusters of nonsmall-cell lung cancer patients according to prognosis," Annals of Oncology, vol. 26, no. 2, pp. 428-435, 2015.
43. A. Carus, H. Gurney, V. Gebski et al., "Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia," Journal of Translational Medicine, vol. 11, article 189, 2013.
44. K. Sánchez-Lara, J. G. Turcott, E. Juárez et al., "Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study," Nutrition and Cancer, vol. 64, no. 4, pp. 526-534, 2012.
45. P.-A. Oldenborg, H. D. Gresham, and F. P. Lindberg, "CD47-signal regulatory protein α (SIRPα) regulates Fcγ and complement receptor-mediated phagocytosis," The Journal of Experimental Medicine, vol. 193, no. 7, pp. 855-862, 2001.
46. L. Bingle, N. J. Brown, and C. E. Lewis, "The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies," The Journal of Pathology, vol. 196, no. 3, pp. 254-265, 2002.
47. A. Mantovani, A. Sica, and M. Locati, "New vistas on macrophage differentiation and activation," European Journal of Immunology, vol. 37, no. 1, pp. 14-16, 2007.
48. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, "Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes," Trends in Immunology, vol. 23, no. 11, pp. 549-555, 2002.
49. S. Gordon, "Alternative activation of macrophages," Nature Reviews Immunology, vol. 3, no. 1, pp. 23-35, 2003.
50. J. G. Quatromoni and E. Eruslanov, "Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer," American Journal of Translational Research, vol. 4, no. 4, pp. 376-389, 2012.
51. C.-I. Chang, J. C. Liao, and L. Kuo, "Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity," Cancer Research, vol. 61, no. 3, pp. 1100-1106, 2001.
52. S. K. Biswas, A. Sica, and C. E. Lewis, "Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms," The Journal of Immunology, vol. 180, no. 4, pp. 2011-2017, 2008.
53. A. Yuan, Y. J. Hsiao, H. Y. Chen et al.,"Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression," Scientific Reports, vol. 5, article 14273, 2015.
54. B. Al-Sarireh and O. Eremin, "Tumour-Associated Macrophages (TAMS): disordered function, immune suppression and progressive tumour growth," Journal of the Royal College of Surgeons of Edinburgh, vol. 45, no. 1, pp. 1-16, 2000.
55. A. Erroi, M. Sironi, F. Chiaffarino, C. Zhen-Guo, M. Mengozzi, and A. Mantovani, "IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma," International Journal of Cancer, vol. 44, no. 5, pp. 795-801, 1989.
56. P. Ghezzi, A. Erroi, R. Acero, M. Salmona, and A. Mantovani, "Defective production of reactive oxygen intermediates by tumor-associated macrophages exposed to phorbol ester," Journal of Leukocyte Biology, vol. 42, no. 1, pp. 84-90, 1987.
57. C. E. Lewis, R. Leek, A. Harris, and J. O. McGee, "Cytokine regulation of angiogenesis in breast cancer: the role of tumorassociated macrophages," Journal of Leukocyte Biology, vol. 57, no. 5, pp. 747-751, 1995.
58. J. D. Brain, "Macrophage damage in relation to the pathogenesis of lung diseases," Environmental Health Perspectives, vol. 35, pp. 21-28, 1980.
59. W. Wang, H. Liu, X. Dai et al., "p53/PUMA expression in human pulmonary fibroblasts mediates cell activation and migration in silicosis," Scientific Reports, vol. 5, article 16900, 2015.
60. S. Hodge, G. Hodge, J. Ahern, H. Jersmann, M. Holmes, and P. N. Reynolds, "Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease," American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 6, pp. 748-755, 2007.
61. T. R. Richens, D. J. Linderman, S. A. Horstmann et al., "Cigarette smoke impairs clearance of apoptotic cells through oxidantdependent activation of RhoA," American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 11, pp. 1011-1021, 2009.
62. R. Subramaniam, S. Mukherjee, H. Chen, S. Keshava, P. Neuenschwander, and H. Shams, "Restoring cigarette smoke-induced impairment of efferocytosis in alveolar macrophages," Mucosal Immunology, 2015.
63. S. Sone, "Role of alveolar macrophages in pulmonary neoplasias," Biochimica et Biophysica Acta, vol. 823, no. 3, pp. 227-245, 1986.
64. I. L. Bonta and S. Ben-Efraim, "Involvement of inflammatory mediators in macrophage antitumor activity," Journal of Leukocyte Biology, vol. 54, no. 6, pp. 613-626, 1993.
65. C. M. Ohri, A. Shikotra, R. H. Green, D. A. Waller, and P. Bradding, "Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival," European Respiratory Journal, vol. 33, no. 1, pp. 118-126, 2009.
66. J. Ma, L. Liu, G. Che, N. Yu, F. Dai, and Z. You, "The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time," BMC Cancer, vol. 10, article 112, 2010.
67. J. S. Lopez-Gonzalez, F. Avila-Moreno, H. Prado-Garcia, D. Aguilar-Cazares, J. J. Mandoki, and M. Meneses-Flores, "Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-α," Clinical Immunology, vol. 122, no. 3, pp. 323-329, 2007.
68. A. Mantovani, A. Sica, and M. Locati, "Macrophage polarization comes of age," Immunity, vol. 23, no. 4, pp. 344-346, 2005.
69. X. Fu, H. Shi, Y. Qi, W. Zhang, and P. Dong, "M2 polarized macrophages induced by CSE promote proliferation, migration, and invasion of alveolar basal epithelial cells," International Immunopharmacology, vol. 28, no.1, pp. 666-674, 2015.
70. Y. Kobayashi, "Neutrophil biology: an update," EXCLI Journal, vol. 14, pp. 220-227, 2015.
71. J. Seok, H. S. Warren, A. G. Cuenca et al., "Genomic responses in mouse models poorly mimic human inflammatory diseases," Proceedings of the National Academy of Sciences of the United States of America,vol.110,no.9,pp.3507-3512,2013.
72. E. B. Eruslanov, P. S. Bhojnagarwala, J. G. Quatromoni et al., "Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer," The Journal of Clinical Investigation, vol. 124, no. 12, pp. 5466-5480, 2014.
73. Z. G. Fridlender, J. Sun, S. Kim et al., "Polarization of tumorassociated neutrophil phenotype by TGF-β: 'N1' versus 'N2' TAN," Cancer Cell, vol. 16, no. 3, pp. 183-194, 2009.
74. C. N. Serhan and J. Savill, "Resolution of inflammation: the beginning programs the end," Nature Immunology, vol. 6, no. 12, pp. 1191-1197, 2005.
75. H. Mora-Jensen, J. Jendholm, A. Fossum, B. Porse, N. Borregaad, and K. Theilgaard-Mönch, "Technical advance: immunophenotypical characterization of human neutrophil differentiation," Journal of Leukocyte Biology, vol. 90, no. 3, pp. 629-634, 2011.
76. M. P. Colombo, G. Ferrari, A. Stoppacciaro et al., "Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo," The Journal of Experimental Medicine, vol. 173, no. 4, pp. 889-897, 1991.
77. M. H. Kang, S.-I. Go, H.-N. Song et al., "The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with smallcell lung cancer," British Journal of Cancer, vol. 111, no. 3, pp. 452-460, 2014.
78. Y. Liu, D. Merlin, S. L. Burst, M. Pochet, J. L. Madara, and C. A. Parkos, "The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47," The Journal of Biological Chemistry, vol. 276, no. 43, pp. 40156-40166, 2001.
79. N. G. Sosale, K. R. Spinler, C. Alvey, and D. E. Discher, "Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self ' CD47, and target physical properties," Current Opinion in Immunology, vol. 35, pp. 107-112, 2015.
80. S. B. Willingham, J.-P. Volkmer, A. J. Gentles et al., "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 17, pp. 6662-6667, 2012.
81. M. P. Chao, I. L. Weissman, and R. Majeti, "The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications," Current Opinion in Immunology, vol. 24, no. 2, pp. 225-232, 2012.
82. R. K. Tsai and D. E. Discher, "Inhibition of 'self' engulfment through deactivation of myosin-II at the phagocytic synapse between human cells," The Journal of Cell Biology, vol. 180, no. 5, pp. 989-1003, 2008.
83. E. J. Brown and W. A. Frazier, "Integrin-associated protein (CD47) and its ligands," Trends in Cell Biology, vol. 11, no. 3, pp. 130-135, 2001.
84. F. P. Lindberg, H. D. Gresham, E. Schwarz, and E. J. Brown, "Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membranespanning domains implicated in alpha v beta 3-dependent ligand binding," The Journal of Cell Biology, vol. 123, no. 2, pp. 485-496, 1993.
85. F. P. Lindberg, D. C. Bullard, T. E. Caver, H. D. Gresham, A. L. Beaudet, and E. J. Brown, "Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice," Science, vol. 274, no. 5288, pp. 795-798, 1996.
86. D. R. Soto-Pantoja, S. Kaur, and D. D. Roberts, "CD47 signaling pathways controlling cellular differentiation and responses to stress," Critical Reviews in Biochemistry and Molecular Biology, vol. 50, no. 3, pp. 212-230, 2015.
87. A. N. Barclay and T. K. Van den Berg, "The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target," Annual Review of Immunology, vol. 32, pp. 25-50, 2014.
88. S. Jaiswal, M. P. Chao, R. Majeti, and I. L. Weissman, "Macrophages as mediators of tumor immunosurveillance," Trends in Immunology, vol. 31, no. 6, pp. 212-219, 2010.
89. P.-A. Oldenborg, A. Zheleznyak, Y.-F. Fang, C. F. Lagenaur, H. D. Gresham, and F. P. Lindberg, "Role of CD47 as a marker of self on red blood cells," Science, vol. 288, no. 5473, pp. 2051-2054, 2000.
90. S. Jaiswal, C. H. M. Jamieson, W. W. Pang et al., "CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis," Cell, vol. 138, no. 2, pp. 271-285, 2009.
91. D. D. Roberts, S. Kaur, and D. R. Soto-Pantoja, "Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer," Journal of Cell Communication and Signaling, vol.9, no. 1, pp. 101-102, 2015.
92. E. Sick, A. Boukhari, T. Deramaudt et al., "Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway," Glia, vol. 59, no. 2, pp. 308-319, 2011.
93. D. W. Lawrence, S. B. King, W. A. Frazier, and J. M. Koenig, "Decreased CD47 expression during spontaneous apoptosis targets neutrophils for phagocytosis by monocyte-derived macrophages," Early Human Development, vol. 85, no. 10, pp. 659-663, 2009.
94. Y. Wang, Z. Xu, S. Guo et al., "Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis," Molecular Therapy, vol.21, no.10, pp. 1919-1929, 2013.
95. Y. Murata, T. Kotani, H. Ohnishi, and T. Matozaki, "The CD47-SIRPα signalling system: its physiological roles and therapeutic application," Journal of Biochemistry, vol. 155, no. 6, pp. 335-344, 2014.
96. G. H. Su and Y. L. Zhao, "Role of CD47 in hematologic malignancies," Journal of experimental hematology/Chinese Association of Pathophysiology, vol. 21, no. 6, pp. 1631-1634, 2013.
97. S. Khandelwal, N. Van Rooijen, and R. K. Saxena, "Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation," Transfusion, vol. 47, no. 9, pp. 1725-1732, 2007.
98. J. Savill and V. Fadok, "Corpse clearance defines the meaning of cell death," Nature, vol. 407, no. 6805, pp. 784-788, 2000.
99. S. Greenberg and S. Grinstein, "Phagocytosis and innate immunity," Current Opinion in Immunology, vol. 14, no. 1, pp. 136-145, 2002.
100. S. A. Myers, W. H. DeVries, K. R. Andres et al., "CD47 knockout mice exhibit improved recovery from spinal cord injury," Neurobiology of Disease, vol. 42, no. 1, pp. 21-34, 2011.
101. Y. Liu, M. B. O'Connor, K. J. Mandell et al., "Peptide-mediated inhibition of neutrophil transmigration by blocking CD47 interactions with signal regulatory protein α," The Journal of Immunology, vol. 172, no. 4, pp. 2578-2585, 2004.
102. K. Zen, Y. Guo, Z. Bian et al., "Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state," Nature Communications, vol. 4, article 2436, 2013.
103. W. Y. Lee, D. A. Weber, O. Laur et al., "The role of cis dimerization of signal regulatory protein α (SIRPα) in binding to CD47," The Journal of Biological Chemistry, vol. 285, no. 49, pp. 37953-37963, 2010.
104. Y. Liu, I. Soto, Q. Tong et al., "SIRPβ1 is expressed as a disulfidelinked homodimer in leukocytes and positively regulates neutrophil transepithelial migration," The Journal of Biological Chemistry, vol. 280, no. 43, pp. 36132-36140, 2005.
105. Y. Liu, H.-J. Bühring, K. Zen et al., "Signal regulatory protein (SIRPα), a cellular ligand for CD47, regulates neutrophil transmigration," The Journal of Biological Chemistry, vol. 277, no. 12, pp. 10028-10036, 2002.
106. M. J. Finley, L. Rauova, I.S. Alferiev, J. W. Weisel, R. J. Levy, and S. J. Stachelek, "Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces," Biomaterials, vol. 33, no. 24, pp. 5803-5811, 2012.
107. S. J. Stachelek, M. J. Finley, I. S. Alferiev et al., "The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation," Biomaterials, vol. 32, no. 19, pp. 4317-4326, 2011.
108. X. W. Zhao, E. M. Van Beek, K. Schornagel et al., "CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 45, pp. 18342-18347, 2011.
109. D. Hoelzer and N. Gökbuget, "T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?" Clinical Lymphoma & Myeloma, vol. 9, supplement 3, pp. S214-S221, 2009.
110. K. S. Chan, I. Espinosa, M. Chao et al., "Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14016-14021, 2009.
111. R. Majeti, M. P. Chao, A. A. Alizadeh et al., "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells," Cell, vol. 138, no. 2, pp. 286- 299, 2009.
112. M. P. Chao, A. A. Alizadeh, C. Tang et al., "Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma," Cell, vol. 142, no. 5, pp. 699-713, 2010.
113. C. Naujokat, "Monoclonal antibodies against human cancer stem cells," Immunotherapy, vol. 6, no. 3,pp. 290-308, 2014.
114. O. Gires, "Lessons from common markers of tumor-initiating cells in solid cancers," Cellular and Molecular Life Sciences, vol. 68, no. 24, pp. 4009-4022, 2011.
115. K. S. Chan, J.-P. Volkmer, and I. Weissman, "Cancer stem cells in bladder cancer: a revisited and evolving concept," Current Opinion in Urology, vol. 20, no. 5, pp. 393-397, 2010.
116. H.-S. Ju, X.-J. Li, B.-L. Zhao, J.-W. Hou, Z.-W. Han, and W.-J. Xin, "Scavenging effects of sodium ferulate and 18 beta-glycyrrhetic acid on oxygen free radicals," Acta Pharmacologica Sinica, vol. 11, no. 5, pp. 466-470, 1990.
117. I. Weissman, "Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke," Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 370, no. 1680, 2015.
118. P. K. Gautam and A. Acharya, "Suppressed expression of homotypic multinucleation, extracellular domains of CD172alpha (SIRP-alpha) and CD47 (IAP) receptors in TAMs upregulated by Hsp70-peptide complex in Dalton's lymphoma," Scandinavian Journal of Immunology, vol. 80, no. 1, pp. 22-35, 2014.
119. I. Baccelli, A. Schneeweiss, S. Riethdorf et al., "Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay," Nature Biotechnology, vol. 31, no. 6, pp. 539-544, 2013.
120. J. B. Maxhimer, D. R. Soto-Pantoja, L. A. Ridnour et al., "Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling," Science Translational Medicine, vol. 1, no. 3, article 3ra7, 2009.
121. M. Cieslewicz, J. Tang, J. L. Yu et al., "Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 40, pp. 15919-15924, 2013.
122. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al., "CSF-1R inhibition alters macrophage polarization and blocks glioma progression," Nature Medicine, vol. 19, no. 10, pp. 1264-1272, 2013.
123. Y.-Q. Chen and G. Chen, "Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice," Journal of Cancer Research and Therapeutics, vol. 11, no. 2, pp. 324-330, 2015.
124. L. Ding, G. Liang, Z. Yao et al., "Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages," Oncotarget, vol. 6, no. 34, pp. 36441-36455, 2015.
125. K. Isoda, J. L. Young, A. Zirlik et al., "Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 611-617, 2006.
126. L. Li, W. Huang, K. Li et al., "Metformin attenuates gefitinibinduced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway," Oncotarget, vol. 6, no. 41, pp. 43605-43619, 2015.
127. C. Kunert-Keil, F. Steinmüller, U. Jeschke, T. Gredes, and T. Gedrange, "Immunolocalization of glycodelin in human adenocarcinoma of the lung, squamous cell carcinoma of the lung and lung metastases of colonic adenocarcinoma," Acta Histochemica, vol. 113, no. 8, pp. 798-802, 2011.
128. E. I. Buchbinder and A. Desai, "CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition," American Journal of Clinical Oncology, 2015.
129. A. D'Incecco, M. Andreozzi, V. Ludovini et al., "PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients," British Journal of Cancer, vol. 112, no. 1, pp. 95-102, 2015.
130. R. K. Beckers, C. I. Selinger, R. Vilain et al., "PDL1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome," Histopathology, 2015.
131. F. Dallegri and L. Ottonello, "Neutrophil - mediated cytotoxicity against tumour cells: state of art," Archivum Immunologiae et Therapiae Experimentalis, vol. 40, no. 1, pp. 39-42, 1992.